SIBIONICS

Established in 2015 by a team of 30 scientists from the USA and China, SIBIONICS is a medical technology company specializing in the development and commercialization of advanced medical solutions for chronic disease management. The company has secured significant financial backing, raising a total of $165M, including a Series C round that garnered over $126 million and a Series D round of nearly $72 million from investors such as China New Town Development, CPE, and Sequoia.

SIBIONICS operates in the global MedTech and digital health markets, focusing on providing long-term monitoring solutions. The company's business model revolves around the research, development, and sale of biowearable devices. Its primary clients include individuals with diabetes, healthcare professionals, and hospitals. As of November 2023, the company had collaborated with 1,600 hospitals for inpatient treatment and served over 600,000 users. By 2025, its user base has grown to 2.6 million people in over 96 countries.

The company's flagship product is the GS1 Continuous Glucose Monitoring (CGM) System, a wearable device that provides real-time glucose readings for 14 days without finger-prick calibration. This system includes a sensor that measures glucose levels and sends the data to a mobile app, which can then generate professional Ambulatory Glucose Profile (AGP) reports. Key features include customizable alerts, data sharing with family or healthcare providers via the ProView remote platform, and an IP28 waterproof rating. In addition to the GS1 CGM, SIBIONICS has developed the KS1 Continuous Ketone Monitoring (CKM) system, a consumer-grade biowearable for metabolic management. The company also leverages artificial intelligence and medical imaging for developing solutions for diabetic retinopathy and gastric cancer screening.

A significant milestone was achieved in November 2023 when the GS1 CGM system received the CE Mark, certifying its compliance with EU health and safety standards and enabling its distribution in the European market. The product first received marketing approval in China in 2021. The company reports an annual production capacity of six million units and has a workforce of over 700, with more than 40% engaged in research and development.

Keywords: Continuous Glucose Monitoring, CGM, MedTech, Digital Health, Diabetes Management, Biowearables, Chronic Disease Management, Medical Devices, Health Monitoring, Artificial Intelligence in Healthcare, Ketone Monitoring, Ambulatory Glucose Profile, GS1 CGM, KS1 CKM, Remote Patient Monitoring, Medical Imaging AI, Health Technology, Wearable Sensors, Diabetes Care, Metabolic Management